Market Signal Briefing

Analyst’s Disclosure: I/we have a beneficial long position in the shares of FLC, DHF either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

While Palantir (PLTR) is a stock Aquiles Larrea, Jr. considers a key part of portfolios, he shows concern in valuations. To justify the company's "quite expensive" price tag, Aquiles expects Palantir to show strong growth in earnings after Monday's close.

Alphabet's fourth-quarter results are expected to benefit from AI-powered Search and Cloud growth, but rising costs and stiff competition pose risks.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Walt Disney (NYSE:DIS), the long-standing theme park behemoth that’s now a streaming service contender, just released its latest round of quarterly data. Usually Disney stock isn’t particularly volatile, but Monday’s share-price action brought surprises and a bit of whiplash.

It’s been a major challenge for Disney’s streaming service, Disney+, to keep up with competitors like Netflix (NASDAQ:NFLX). Furthermore, after the film Snow White bombed at the box office last year, investors may wonder whether Disney has lost its magic touch in the mid-2020s.

Much was revealed on Monday as Disney released its first-quarter results for fiscal year 2026 along with executive commentary from CEO Bob Iger and CFO Hugh Johnston. Still, with the trajectory of Disney stock turning negative and the $100 support level hanging in the balance, it’s only getting tougher to make a bullish case for the remainder of 2026.

DIS Stock Pop and Drop It’s always interesting to witness the market’s reaction to big-business earnings releases in real time. Short-term traders dominate the price action as they scramble to assess and act upon the newly available data.

Disney stock has been all over the place, going nowhere fast during the past 12 months. Monday morning’s premarket earnings report offered an opportunity for DIS stockholders to possibly enjoy a strong start to the new year.

Yet, there was only more whiplash and disappointment to start off the week. Disney stock initially zoomed higher at first, even hitting $117.50 for a hot minute after the quarterly earnings release.

The celebratory mood didn’t last long, though. By 10:00 a.m. Eastern time, DIS stock was under $105, raising fears of a psychologically damaging potential break below $100.

All of this occurred even as Disney reported an earnings beat and, in one segment at least, record revenue and operating income for the quarter. Making sense of the chaotic share-price movement requires a deeper dive into the data and executive commentary, so let’s jump right in.

Headline Numbers: What You Need to Know The pop-and-drop price action of DIS stock may be a function of the mix of good and not-so-good news. For example, it’s moderately good news that Disney’s Q1 FY2026 revenue increased 5% year over year to $26 billion.

That’s not a terrible result, and that $26 billion quarterly revenue figure is nearly in line with the analysts’ consensus estimate. Also, Disney’s Entertainment division revenue rose 7% compared to the first quarter of fiscal 2025.

Moreover, revenue for Disney’s Experiences segment (which includes theme parks) grew 6% to $11.609 billion. On the other hand, revenue for the company’s Sports division, a relatively minor but still important component of Disney’s business, only rose 1% to $4.909 billion.

Meanwhile, Disney’s Experiences division operating income expanded 6% to $3.309 billion — again, a respectable result if your expectations aren’t sky-high. However, the company’s Entertainment operating income declined 35% to $1.1 billion and Disney’s Sports operating income fell 23% to $191 million.

All in all, Disney’s total segment operating income fell 9% to $4.6 billion, and the company’s diluted EPS excluding certain items declined 7% to $1.63. This result beats the analysts’ consensus estimate of earnings of $1.57 per share, but it still represents a disappointing year-on-year decline.

Record Setting Isn’t Enough In Disney’s executive commentary letter, Iger and Johnston boasted that the company’s Experiences division “delivered record quarterly revenue and operating income in Q1.” They also touted the Disney films Zootopia 2 and Avatar: Fire and Ash, which “crossed the $1 billion mark at the global box office.”

That’s all fine and well, but Iger and Johnston also acknowledged the decrease in Disney’s Entertainment segment operating income. This, they posited, reflected “higher programming and production and marketing costs driven by more theatrical releases in the quarter.”

Specifically, Disney reported nine theatrical releases in Q1 FY2026 versus only four in the year-earlier quarter. It appears, then, that Disney’s “more is better” approach to theatrical releases could negatively impact the company’s bottom-line results.

Additionally, it looks like Disney is jumping headfirst onto the artificial intelligence (AI) bandwagon. On that topic, Iger and Johnston bragged about the rollout of “numerous product enhancements to elevate the user experience on Disney+” as the company explores “opportunities to use AI to further increase personalization.”

In early 2026, AI technology integration might not be as novel and exciting as it once was. Investors want to see results from heavy AI spend, not just promises of an “elevated” Disney+ user experience.

Besides, Iger and Johnston can talk about setting records if they want to, but this wasn’t enough to keep DIS stock afloat for very long. Now, the share price is dangerously close to $100 and, for prudent investors, it makes sense to watch, wait, and hope for better financial results instead of just executive-level ambitions.

If You’ve Been Thinking About Retirement, Pay Attention (sponsor) Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance, and SmartAsset’s simple quiz makes it easier than ever for you to connect with a vetted financial advisor. Here’s how:

Answer a few simple questions Get Matched with Vetted Advisors  Choose Your  Fit  Why wait? Start building the retirement you’ve always dreamed of. Get started today! (sponsor)

For Tesla (NASDAQ:TSLA) and its investors, the times are changing rapidly.

Tenet Healthcare Corporation (THC) Discusses Accretive Asset Sale of Conifer Revenue Cycle Management Services Contract with CommonSpirit February 2, 2026 10:00 AM EST

Company Participants

William McDowell - Vice President of Investor Relations
Saumya Sutaria - Chairman & CEO
Sun Park - Executive VP & CFO

Conference Call Participants

Brian Tanquilut - Jefferies LLC, Research Division
Marco Criscuolo - Nephron Research LLC
Albert Rice - UBS Investment Bank, Research Division
Justin Lake - Wolfe Research, LLC
Sarah James
Benjamin Mayo - Leerink Partners LLC, Research Division
Craig Hettenbach - Morgan Stanley, Research Division
Kevin Fischbeck - BofA Securities, Research Division

Presentation

Operator

Greetings. Welcome to the Tenet Healthcare Analyst Conference Call. [Operator Instructions] Please note, this conference is being recorded.

I will now turn the conference over to Will McDowell, Tenet's Vice President of Investor Relations. Thank you, you may begin.

William McDowell
Vice President of Investor Relations

Good morning, everyone, and thank you for joining today's call. I am Will McDowell, Vice President of Investor Relations. We're pleased to have you join us for a discussion of Tenet's announcement of our accretive Conifer transaction. Tenet senior management participating in today's call will be Dr. Saum Sutaria, Chairman and Chief Executive Officer; and Sun Park, Executive Vice President and Chief Financial Officer.

Listeners to this call are advised that certain statements made during our discussion today are forward-looking and represent management's expectations based on currently available information. Actual results and plans could differ materially. Tenet is under no obligation to update any forward-looking statements based on subsequent information. Investors should take note of the cautionary statement in today's press release as well as the risk factors discussed in our most recent Form 10-K and other filings with the Securities and Exchange Commission.

One note before I turn the call over to Saum, as we discussed in today's release, our

Key Takeaways RBLX to report Q4 results on Feb. 5, with revenues seen at $2.07B, up 52.1% from last year.User growth and engagement accelerated, led by Asia-Pacific, expanding the paying base and bookings.Regional pricing lifted payer counts, but higher DevEx payouts and spending pressured profitability. Roblox Corporation (RBLX - Free Report) is scheduled to release fourth-quarter 2025 results on Feb 5. In the last reported quarter, the company’s earnings surpassed the Zacks Consensus Estimate by 30.2%.

RBLX has an impressive record of beating earnings expectations. Its earnings have surpassed the consensus mark in each of the trailing four quarters, with an average surprise of 22.8%.

RBLX’s Q4 Estimate RevisionsThe Zacks Consensus Estimate for Roblox’s fourth-quarter 2025 loss per share is pegged at 49 cents. In the prior year quarter, the company reported an adjusted loss per share of 33 cents. The consensus mark has narrowed by a cent in the past 30 days.

The Zacks Consensus Estimate for revenues is pegged at $2.07 billion, indicating a 52.1% rise from the year-ago quarter's reported figure.

Factors to Influence RBLX’s Q4 PerformanceThe company’s top line in the fourth quarter of 2025 is likely to have been aided by strong underlying momentum in user growth and engagement, which accelerated through the second half of the year. Daily active users and total hours continued to expand rapidly across regions, with particularly strong traction in Asia-Pacific markets and emerging countries. This geographic expansion materially increased the size of the addressable paying base, helping sustain bookings and revenue growth even as monetization levels varied by region.

Another key tailwind is the continued strength and diversification of the content ecosystem. Management highlighted that engagement growth outside the top 10 experiences accelerated meaningfully, reflecting a broader set of viral hits and more consistent performance from mid-tier and newer experiences. This has reduced reliance on a handful of titles and supported steadier monetization across the platform, especially during a seasonally strong quarter like the fourth quarter.

Improved monetization mechanics are also likely to have aided the top line. The rollout of regional pricing in the marketplace has increased payer penetration in price-sensitive markets, helping monthly unique payers grow faster than overall users. While spend per payer has declined on a blended basis due to geographic mix, the sharp increase in the number of payers and continued growth in bookings per DAU in core regions have supported overall revenue expansion in fourth-quarter 2025.

Ongoing enhancements to discovery, platform performance and creator tools are likely to have reinforced engagement and spending. Investments in recommendation transparency, infrastructure scalability and early-stage AI-driven improvements have helped surface new experiences, sustain high concurrency levels and keep users active for longer periods. These factors are likely to have collectively supported stronger seasonal demand and higher gross bookings during the quarter.

Despite robust top-line growth, profitability in fourth-quarter 2025 is likely to have pressured by elevated investment spending. A higher Developer Exchange (DevEx) rate has increased the share of bookings paid out to creators, directly raising the cost of revenues and weighing on margins. This impact was amplified by record creator earnings volumes as platform engagement surged.

In addition, infrastructure and safety-related costs are likely to have remained elevated. Management emphasized continued spending on data centers, GPU capacity and trust-and-safety initiatives, including new policies and AI-driven systems. While these investments are intended to have supported long-term growth and platform resilience, they have limited near-term margin expansion during fourth-quarter 2025.

Q4 Earnings Whispers for RBLXOur proven model does not predict an earnings beat for Roblox this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat.

RBLX’s Earnings ESP: Roblox has an Earnings ESP of -42.22%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.

RBLX’s Zacks Rank: The company carries a Zacks Rank #3 at present.

Stocks Poised to Beat on EarningsHere are some stocks from the Zacks Consumer Discretionary sector that investors may consider, as our model shows that these have the right combination of elements to post an earnings beat.

Choice Hotels International, Inc. (CHH - Free Report) has an Earnings ESP of +1.42% and a Zacks Rank of 3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

For the to-be-reported quarter, Choice Hotels’ earnings are expected to remain flat year over year. Choice Hotels reported better-than-expected earnings in two of the trailing four quarters and missed on two occasions, the average miss being 0.6%.

Hilton Worldwide, Inc. (HLT - Free Report) currently has an Earnings ESP of +3.08% and a Zacks Rank of 3.

For the to-be-reported quarter, Hilton’s earnings are expected to increase 17.6%. Hilton Worldwide reported better-than-expected earnings in each of the trailing four quarters, the average surprise being 5.8%.

Marriott International, Inc. (MAR - Free Report) currently has an Earnings ESP of +4.21% and a Zacks Rank of 3.

For the to-be-reported quarter, Marriott’s earnings are expected to increase 11.4%. Marriott International reported better-than-expected earnings in each of the trailing four quarters, the average surprise being 2%.

In a move that underscores the relentless downward pressure on investment costs, Vanguard announced today that it has slashed fees for 84 mutual fund and exchange-traded share classes. These reductions, spanning 53 different funds, represent nearly $250 million in estimated savings for investors in 2026 alone.

This latest round of cuts brings the firm’s two-year total savings to approximately $600 million, marking the largest two-year combined cost reduction in Vanguard’s history, according to a statement from the firm. For financial advisors, the move reinforces Vanguard’s role in making investing more accessible, affordable, and efficient for investors over the past 50 years. The average Vanguard expense ratio across its entire lineup now sits at just 0.06%.

“The fee reductions are a great post-holiday present to existing Vanguard fund shareholders,” Todd Rosenbluth, head of research at VettaFi, said. “While we continue to believe ETF selection should go deeper than a review of expense ratio, these savings will help investors achieve their financial goals.” 

Broad-Based Reductions Across Asset Classes The fee migrations were not localized to a single niche but extended across 25% of the firm’s total fund lineup. The average reduction for the specific funds receiving a cut this year is 27%.

Among the notable ETFs impacted are the Vanguard Growth ETF (VUG) and the Vanguard Value ETF (VTV). Additionally, international and factor-based strategies saw adjustments, including the FTSE Emerging Markets ETF (VWO) and popular income plays like the Dividend Appreciation ETF (VIG) and the High Dividend Yield ETF (VYM).

The fee cuts reveal a particularly aggressive stance in the fixed-income sector. Currently, 100% of Vanguard’s active fixed-income funds and 89% of its fixed-income ETFs are priced in the lowest cost decile of their respective categories, according to the firm.

“Vanguard is investor-owned – we have no outside stockholders or inside owners profiting from our clients. These fee reductions – more than half a billion dollars over the past two years—are a clear expression of our purpose and commitment to our clients as owners,” Salim Ramji, Vanguard’s CEO, said in a statement. “When investors keep more of what they earn, the benefits compound over the long term, helping our clients achieve their most important financial goals.”

Vanguard Cuts Fees: What This Means for Advisors For advisors, the correlation between cost and performance remains the primary selling point. Vanguard reports that 84% of its funds have outperformed peer group averages over the past decade. This outperformance is even more pronounced in the active fixed income space, where 88% of Vanguard’s active fixed-income funds beat their benchmarks.

While these cuts strengthen Vanguard’s position in the industry, they also challenge advisors to justify the use of higher-cost active managers in portfolios.

Originally published on Advisor Perspectives

For more news, information, and strategy, visit the Fixed Income Content Hub.

Earn free CE credits and discover new strategies

Nvidia and Oracle are sending similar warning signs about the AI trade

Skip to main content Explore Our Brands

WSJ Barron's MarketWatch IBD WSJ | Buy Side Site Search

Search Results

Symbols

No results found

All NewsArticlesVideoPodcasts0

Results

No Results Found

Authors

No results found

Sections

No results found

Columns

No results found

HomeIndustriesComputers/ElectronicsTech StocksTech StocksOracle is raising more debt and Nvidia is walking back its OpenAI investment target. Both are signs that the AI trade could be on shaky ground, according to one analyst.Published: Feb. 2, 2026 at 11:23 a.m. ET

Nvidia and Oracle are at the center of OpenAI’s trillion-dollar web of financing, but recent developments at the two companies may be sending cautious signals about the health of the artificial-intelligence trade, according to an analyst.  

On Sunday, Oracle ORCL announced plans to raise up to $50 billion in 2026 to fund its cloud growth. The money will be raised through a combination of debt and equity to support the infrastructure needs of key customers such as Advanced Micro Devices AMD, Meta Platforms META, Nvidia NVDA, OpenAI, TikTok and xAI.

Partner CenterMost PopularAbout the Author

Britney Nguyen is a tech reporter covering Nvidia, chips and AI. You can find her on X at @britneycath.

Christine Ji is a reporter covering Big Tech.

Intraday Data provided by

FACTSET

and subject to

terms of use.

Historical and current end-of-day data provided by

FACTSET. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.

3 Marijuana Stocks To Watch In The Market 2026

3 minute read Here Are 3 Marijuana Stocks For Investing This Month 2026 is another big moment for legal cannabis operators in the US and other parts around the globe. This year is another time of change that will shape how legal cannabis will proceed for various markets. In the USA, cannabis is now a Schedule 3, helping with different aspects of cannabis. With this change, cannabis can now be researched further, and the attempt to pass banking reform becomes more favored.

These changes also help build bridges between different global players to work with US cannabis businesses. Investing in marijuana stocks is on the rise, with the speculation of what is soon to come. For example, more cannabis products are being accessed in different markets across the world. There is big money being made in legal cannabis if you are in the correct sector. Ancillary cannabis stocks tend to benefit from the volatility, as they are not solely dependent on the flower itself.

Nevertheless, there is an opportunity in the space, and preparing for it is important. The more you can learn that adds value to your trading plan, the better your odds of taking your profits. Legal cannabis keeps growing in acceptance, and money is being made by big legal operators throughout the sector. Below are several marijuana stocks to watch that could yield profits for shareholders.

Top Marijuana Stocks For Investors Greenlane Holdings, Inc.(NASDAQ:GNLN) Jushi Holdings Inc.(OTC:JUSH) Trulieve Cannabis Corp.(OTC:TCNNF) Greenlane Holdings, Inc. Greenlane Holdings, Inc. engages in the development and distribution of cannabis accessories, vape devices, and lifestyle products in the United States, Canada, Europe, and Latin America.

In recent news, the company announced it will deploy 30 million units of BERA into validator infrastructure. This was done through a partnership with Infrared Finance.

Words From The Company “Partnering with Infrared enables us to participate in Berachain’s validator infrastructure and its associated protocol-level incentive mechanisms through an experienced ecosystem participant,” said Ben Isenberg, Chief Investment Officer of Greenlane.”

Jushi Holdings Inc. Jushi Holdings Inc., a vertically integrated cannabis company, engages in the cultivation, processing, retail, and distribution of cannabis for the medical and adult-use markets in the United States.

On January 21st, the company announced the opening of its 2nd Beyond Hello in Cincinnati, Ohio. This expands the company’s statewide retail footprint to 7 locations in Ohio. Overall, the total number of stores has now increased to 43 across the nation.

[Read More] Best Ancillary Cannabis Stocks to Watch in February 2026

Words From The CEO “Ohio continues to be one of our most strategic growth markets, and the opening of our second Beyond Hello in the Cincinnati area represents another important milestone in our expansion across the state,” said Jim Cacioppo, Chief Executive Officer, Chairman, and Founder of Jushi Holdings Inc.

[Read More] Best U.S. Marijuana Stocks to Follow as February 2026 Begins

Trulieve Cannabis Corp. Trulieve Cannabis Corp. operates as a cannabis retailer. The company cultivates, processes, and manufactures cannabis products and distributes its products to its dispensaries, as well as through home delivery.

Recently, the company announced the closing of a US$60 million private placement of 10.5% senior secured notes. Together with the first offering of Notes, which closed on December 17, 2025, Trulieve has issued Notes in the aggregate principal amount of US$200.0 million.

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | [email protected]

Key Takeaways Eli Lilly's Q4 growth is expected to be fueled by blockbuster GLP-1 drugs and expanding global launches.NVO's Q4 growth hinges on diabetes and obesity drugs like Wegovy and Ozempic amid slowing U.S. momentum.Pfizer's revenue growth is expected to be driven by stronger sales of Vyndaqel, Eliquis, Padcev and Lorbrena. The fourth-quarter 2025 reporting cycle for the Medical sector is about to pick up pace this week, as most firms are slated to share their earnings results over the next two weeks. The sector mainly comprises pharma/biotech and medical device companies. The earnings season for the drug and biotech sector kicked off in late January when bellwether Johnson & Johnson reported strong fourth-quarter results, beating estimates for earnings and sales. J&J consequently issued a 2026 guidance which was above expectations, reflecting the strong growth trend in its Innovative Medicines unit to continue.

While most of the pharma bigwigs are slated to report their earnings results later this week, Roche’s 2025 results were weighed down by unfavorable foreign-exchange movements, as weakness in the U.S. dollar adversely impacted international sales. Nonetheless, the company’s underlying operational performance remained solid. Strong growth of key products, such as Phesgo (breast cancer), Xolair (food allergies), Hemlibra (hemophilia A), Vabysmo (severe eye diseases) and Ocrevus (multiple sclerosis), helped offset declining sales of legacy drugs. On the other hand, Sanofi, which reported fourth-quarter results last week, delivered mixed performance, beating earnings estimates while slightly missing sales expectations. The company nonetheless expects to sustain its profitable growth momentum into 2026.

Per the Earnings Trends report, as of Jan. 28, 11.7% of the companies in the Medical sector — representing 26% of the sector’s market capitalization — reported quarterly earnings. Of these, 85.7% exceeded earnings estimates, while 42.9% topped revenue expectations. Earnings decreased 15.5% year over year, while revenues increased 10.3%. Overall, fourth-quarter earnings of the Medical sector are expected to decrease 2.4%, while sales are projected to rise 8.7% from the year-ago quarter.

Eli Lilly (LLY - Free Report) , Merck (MRK - Free Report) , Novo Nordisk (NVO - Free Report) , Bristol Myers (BMY - Free Report) and Pfizer (PFE - Free Report) are all slated to release theirquarterly results this week. Let us examine how these biotech/pharma companies are likely to have performed in the soon-to-be-reported quarter.

Eli LillyLilly’s performance has been mixed, with the company exceeding earnings expectations in three of the trailing four quarters and missing the same on the remaining occasion. It delivered a four-quarter earnings surprise of 7.44%, on average. In the last reported quarter, LLY delivered an earnings surprise of 16.61%.

Per our proven model, companies with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) have a good chance of delivering an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Lilly has an Earnings ESP of -0.21% and a Zacks Rank #3 at present. The Zacks Consensus Estimate for sales and earnings for the fourth quarter is pegged at $17.87 billion and $6.99 per share, respectively. You can see the complete list of today’s Zacks #1 Rank stocks here.

Lilly is expected to deliver another strong quarter, driven by robust demand for its blockbuster GLP-1 drugs (Mounjaro and Zepbound), improved supply, deeper U.S. market penetration and expanding international launches. Beyond its cardiometabolic portfolio, LLY’s oncology and immunology drugs, including Verzenio, Taltz, and newer launches like Omvoh, Ebglyss and Jaypirca, are also expected to have supported steady top-line expansion in the fourth quarter.

Lilly is scheduled to release its quarterly earnings results before the opening bell on Feb. 4.

MerckMerck has an encouraging earnings track record. It beat earnings estimates in each of the last four quarters, delivering an average earnings surprise of 5.08%. In the last reported quarter, MRK beat earnings estimates by 9.32%.

Merck has an Earnings ESP of +0.03% and a Zacks Rank #4 (Sell) at present. The Zacks Consensus Estimate for sales and earnings for the fourth quarter is pegged at $16.19 billion and $2.03 per share, respectively.

Merck’s top-line growth in the fourth quarter is likely to have been primarily driven by higher sales of its blockbuster cancer drug Keytruda, attributable to rapid uptake across earlier-stage indications globally, particularly early-stage non-small cell lung cancer. Continued strong momentum in metastatic indications is also likely to have boosted sales growth.

Merck is scheduled to release its quarterly earnings results before the opening bell on Feb. 3.

Bristol MyersBristol Myers has an excellent earnings track record. BMY’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 20.05%. In the last reported quarter, Bristol Myers’ earnings surpassed estimates by 10.14%.

Bristol Myers has an Earnings ESP of 0.00% and a Zacks Rank #3 at present. The Zacks Consensus Estimate for sales and earnings for the fourth quarter is pegged at $12.25 billion and $1.15 per share, respectively.

Bristol Myers’ revenues in the fourth quarter of 2025 are likely to have been positively impacted by an increase in growth portfolio sales. The growth portfolio primarily comprises Opdivo, Orencia, Yervoy, Reblozyl, Opdualag, Abecma, Zeposia, Breyanzi, Camzyos, Sotyku, Krazati and others. However, total quarterly revenues are likely to have been adversely affected by a decline in sales from the legacy portfolio, which includes Eliquis, Revlimid, Pomalyst, Sprycel and Abraxane, among others.

Bristol Myers is slated to release its quarterly earnings results before the opening bell on Feb. 5.

Novo NordiskNovo Nordisk has a mixed earnings surprise history. NVO’s earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and matched on the remaining occasion, delivering an average earnings surprise of 11.60%. In the last reported quarter, NVO beat earnings estimates by 32.47%.

For the quarter to be reported, Novo Nordisk has an Earnings ESP of +0.09% and a Zacks Rank #4 at present. The Zacks Consensus Estimate for sales and earnings for the fourth quarter is pegged at $12.08 billion and 89 cents per share, respectively.

Novo Nordisk’s fourth-quarter revenues are expected to have been driven by the sale of its diabetes and obesity treatments, particularly semaglutide-based (GLP-1) drugs — Wegovy, Ozempic, and Rybelsus. Despite year-over-year growth, Ozempic and Wegovy sales are likely to have remained under pressure, with growth slowing due to weaker-than-expected U.S. momentum, persistent compounded semaglutide competition, limited Wegovy uptake, and intensifying rivalry from Eli Lilly in the diabetes and obesity markets. However, NVO’s Rare Disease segment is expected to have generated incremental revenues for the company.

Novo Nordisk is slated to release its quarterly earnings results before the opening bell on Feb. 4.

PfizerPfizer has an impeccable earnings track record. PFE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 35.33%. In the last reported quarter, Pfizer’s earnings beat estimates by 31.82%.

For the quarter to be reported, Pfizer has an Earnings ESP of +1.77% and a Zacks Rank #5 (Strong Sell) at present. The Zacks Consensus Estimate for sales and earnings for the fourth quarter is pegged at $16.93 billion and 57 cents per share, respectively.

Pfizer’s top-line revenue growth in the fourth quarter of 2025 is expected to have been driven by the higher sales of products like Vyndaqel family, Eliquis, Padcev and Lorbrena.

Pfizer is scheduled to release its quarterly earnings results before the opening bell on Feb. 3.

Key Takeaways JCI will report Q1 results on Feb. 4, with revenues seen up 4.3% to $5.7B and adjusted EPS rising 31.3%.JCI's Americas, EMEA and Asia Pacific units are expected to post strong double-digit revenue growth.Higher SG&A, realignment costs and foreign currency headwinds may pressure JCI's margins. Johnson Controls International plc (JCI - Free Report) is scheduled to release first-quarter fiscal 2026 (ended December 2025) financial numbers on Feb. 4, before market open.

The company’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters. The average surprise was 5.6%. In the last reported quarter, its earnings of $1.26 per share beat the consensus estimate of $1.20 by 5%.

The consensus estimate for revenues is pegged at $5.7 billion, indicating an increase of 4.3% from the year-ago quarter’s figure. The consensus estimate for adjusted earnings is pinned at 84 cents per share, indicating an increase of 31.3% from the year-ago quarter’s figure.

Key Factors and Estimates to Note Ahead of JCI’s Earnings ReleaseThe Americas segment is expected to have benefited from heating, ventilation and air conditioning (HVAC) platforms in data centers and strength in controls businesses. Our estimate for the segment’s revenues is pegged at $3.73 billion, indicating a 35.9% increase from the year-ago figure.

The Europe, the Middle East, and Africa (EMEA) segment is expected to have benefited from strength in the service, fire and security, and applied HVAC businesses. Our estimate for the segment’s revenues is pegged at $1.27 billion, indicating a 18.2% increase from the year-ago figure.

Solid momentum in the service business and strength in the products and systems business are expected to have supported the performance of the Asia Pacific segment. We expect revenues from the segment to increase 25.4% year over year to $661 million.

However, the escalating selling, general and administrative (SG&A) expenses are expected to have weighed on Johnson Controls’ bottom line. High organizational realignment and separation costs are expected to have pushed up the SG&A expenses, which are likely to have impacted its margins in the fiscal first quarter.

JCI has considerable exposure to overseas markets. Given the company’s substantial international operations, foreign currency headwinds are likely to have marred its profitability.

Earnings WhispersOur proven model does not conclusively predict an earnings beat for Johnson Controls this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here, as elaborated below.

Earnings ESP: JCI has an Earnings ESP of -0.35% as the Most Accurate Estimate is pegged at 83 cents per share, which is lower than the Zacks Consensus Estimate of 84 cents. You can uncover the best stocks before they’re reported with our Earnings ESP Filter.

Zacks Rank: JCI currently carries a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank stocks here.

Stocks With the Favorable CombinationHere are three companies, which according to our model, have the right combination of elements to post an earnings beat this season.

Ingersoll Rand (IR - Free Report) has an Earnings ESP of +0.82% and a Zacks Rank of 3 at present. The company is slated to release fourth-quarter 2025 results on Feb. 12.

Ingersoll Rand’s earnings matched the Zacks Consensus Estimate thrice and missed once in the trailing four quarters, the average surprise being a negative 0.34%.

Allegion plc (ALLE - Free Report) has an Earnings ESP of +0.21% and a Zacks Rank of 3 at present. The company is scheduled to release fourth-quarter 2025 results on Feb. 17.

Allegion’s earnings surpassed the Zacks Consensus Estimate in each of the preceding four quarters, the average surprise being 5.9%.

Watts Water Technologies (WTS - Free Report) has an Earnings ESP of +0.59% and a Zacks Rank of 2 at present. The company is slated to release second-quarter fiscal 2026 results on Feb. 11.

Watts Water’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 10.9%.

Analysis by You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.

Disney parks head Josh D'Amaro is reportedly the frontrunner to be the next CEO. Ricardo Moreira/Getty Images for Disney; Joseph Prezioso/Anadolu Agency via Getty Images 2026-02-02T16:29:37.226Z

Disney experiences chairman Josh D'Amaro is reportedly the frontrunner to be the company's next CEO. Under D'Amaro's leadership, Disney's parks and experiences have been a cash-generating behemoth. The company's latest earnings underscored how important D'Amaro's fiefdom is to Disney. Josh D'Amaro appears to be the frontrunner in the race to be Disney's next CEO, and the Mouse House's latest quarterly earnings showed why.

Disney's experiences business, which D'Amaro oversees, is the backbone of a company that's being weighed down by the struggling pay-TV business and isn't yet lifted up by its streaming profits. And when that part of the business sneezes, the stock catches a cold.

Although the unit generated record profits, and Disney overall beat Wall Street estimates on both revenue and earnings, the stock fell about 5% in early trading.

Investors seemed worried about Disney's reference to "international visitation headwinds" at its US parks. Another possible factor driving down the stock was Disney's year-over-year decline in earnings per share.

Both the record experiences profits and the investor concerns underscore just how important D'Amaro and his fiefdom are to the company.

Bloomberg reported on Monday that Disney's board of directors "is aligning on promoting" D'Amaro to replace longtime CEO Bob Iger, who's planning to retire later this year. Business Insider could not independently confirm the reporting. Disney didn't immediately respond to a request for comment.

Users on the prediction market Kalshi assigned Josh D'Amaro a 92% chance of becoming the next CEO as of Monday morning.

Dana Walden, who runs Disney's entertainment and TV businesses, is widely seen to be the other top contender for the coveted CEO job. Walden has grown the streaming unit, which also turned in record profits in the last quarter. It's crucial to Disney's future, since traditional TV networks are losing their value due to continued cord-cutting.

Still, D'Amaro's division is the profit-generating machine. Disney's parks, cruises, and products accounted for more than 70% of its operating income, despite making up a relatively small slice of its revenue at under 39%.

D'Amaro's experiences segment has also pulled off an impressive feat: consistently reeling in record revenue and hefty profits by making more money from each visitor, without alienating its biggest fans. The Mouse House has raised ticket prices for its US parks in each of the past four years.

Disney said per-person spending at its US parks rose 4% last quarter, though attendance only increased by 1%, due in part to a dip in visits from international guests. That means the company is making more per customer, in part by upselling through Lightning Lane fast passes. While Disney could risk losing lower-income or middle-class visitors if it keeps hiking prices, its results suggest that's not an issue yet.

On Disney's earnings call, one analyst remarked on how the parks business had gone from the worst part of the company's portfolio to its profit engine.

Iger responded that he's "very, very bullish" on the parks business, which has "never been more broad or more diverse."

"We have a healthy competition now at our company, in terms of which of those two businesses is going to essentially prevail as the No. 1 driver of profitability for the company," Iger said, in reference to the experiences and entertainment businesses — though he could also have been slyly nodding at the race between Walden and D'Amaro.

Media analysis Disney More

Read next

CINCINNATI--(BUSINESS WIRE)--Procter & Gamble (NYSE: PG), a Worldwide Olympic and Paralympic Partner, today opened the doors to the “Champions Clubhouse” in the Milano Olympic Village offering a diverse range of athlete pop-up experiences and services curated by P&G brands, as part of the company’s plans to serve approximately 3,500 winter athletes with top-performing products throughout the duration of the Olympic and Paralympic Winter Games Milano Cortina 2026.

Serving Athletes on the Ground in Milano Cortina

For the first time in Olympic and Paralympic Games history, the Champions Clubhouse, located in both the Milano Olympic Village and Cortina Paralympic Village, will offer bespoke experiences and services to champion and celebrate athletes as they strive to perform at their best – just as P&G brands do every day. Activities include:

Head & Shoulders Scalp & Hair Studio: Premium hair and scalp care through personalized analysis, washing, massage and styling to help athletes feel confident before stepping into the spotlight. Gillette Barber Shop: Personalized shaving and beard-care from GilletteLabs and King C. Gillette to help athletes look sharp and performance-ready. Tampax BraidBar: Confidence-boosting braiding services, product sampling and a live DJ to create an energizing pre-competition experience. Gillette Venus Après Shave: A cozy, ski lodge-inspired retreat offering product giveaways and a winter beverage bar. Chinese New Year Celebration: Gillette precision shaves, Pantene® and Head & Shoulders hair wash and style, and traditional Chinese customs and commemorative gifts. Champions Challenge: High-energy gaming matchups, influencer battles and interactive challenges for athletes featuring P&G brands. MiCo to SoCal: Countdown to the LA28 Games: Celebrate the conclusion of the Olympic Winter Games Milano Cortina 2026 and build excitement for LA28 with summer sport-inspired games and giveaways. For every competing athlete at the Olympic and Paralympic Winter Games P&G is also providing an exclusive Welcome Kit stocked with top-performing P&G products to support their comfort, confidence and care at the Olympic and Paralympic Games. Athletes will enjoy premium products to enhance their experience, including:

Luxurious SK-II Heritage PITERA™ Essence Kit First Aid Beauty Ultra Repair Cream Native® Italian Vanilla Gelato deodorant, a debut scent Head & Shoulders Classic Clean shampoo Oral-B toothpaste and dental floss Dash and Lenor laundry detergent and scent beads Alongside the Welcome Kit, P&G brands will provide complimentary products and services to meet the everyday demands of athletes and staff staying in the Olympic and Paralympic Villages, including:

Laundry Services supplied by Dash and Lenor: All athletes in the Olympic and Paralympic Villages of the Olympic and Paralympic Winter Games Milano Cortina 2026 will experience outstanding cleaning performance when they wash their clothes and uniforms in the laundry rooms, using complimentary products from Dash and Lenor, the Official Laundry Products of Milano Cortina 2026. Pampers Little Champions Kit: Developed in consultation with athlete parents, the International Olympic Committee (IOC), International Paralympic Committee (IPC) and Milano Cortina Organizing Committee, Pampers® will provide athletes who are traveling to the Olympic and Paralympic Games with their small children with a kit including premium diapers, wipes and other gifts, to support their little champions. Period Protection: Always® and Tampax will provide period protection products in the restrooms throughout the Olympic and Paralympic Villages. “Consistency is confidence for me,” said Mikaela Shiffrin, Alpine Skiing, USA, three-time Olympic medalist. “When my day is anchored by the same P&G essentials that I use and trust every day, it creates continuity, even in an intense, unpredictable environment like the Olympic Games. This helps me have fewer distractions, more clarity and the space to focus on skiing my best.”

P&G Brands Take Inspiration from the World’s Top Athletes

More than 25 P&G brands across the globe will also launch Olympic and Paralympic Games-inspired campaigns online and in-store, alongside tailored partnerships with leading athletes, highlighting the superior products that give their best every day – just like Olympians and Paralympians. Some athlete partners include:

Figure Skating star Alysa Liu, USA, partnering with Venus Olympic hopefuls and brothers Jack Hughes, Hockey, USA and Quinn Hughes, Hockey, USA, partnering with Bounty® Nine-time Paralympic Gold Medalist Oksana Masters, Para cross-country skiing, USA, partnering with several P&G brands Silver Olympic Medalist Francesca Lollobrigida, Speedskating, Italy, partnering with Head & Shoulders, Dash and Ambipur® Two-time Gold Medalist Anna Gasser, Snowboarding, Austria, partnering with P&G brands including Pantene, Oral-B and Venus Paralympian Giuseppe Romele, Para cross-country skiing, Italy, partnering with P&G brands including Head & Shoulders, Swiffer and Oral-B Paralympic hopeful Audrey Pascual, Para alpine skiing, Spain, partnering with P&G brands including Zzzquil®, Oral-B and Ariel® “For Milano Cortina 2026, our brands continue to be inspired by the dedication and excellence of the best athletes in the world,” commented P&G Chief Brand Officer Marc Pritchard. “Just as athletes work tirelessly to deliver a superior performance when it matters most, our best performing household and personal care products help athletes, fans and households stay focused on achieving their best – on the Olympic or Paralympic stage and in everyday life.”

Advancing Access and Inclusion to Para Sport Across Italy

As a longstanding partner of the Paralympic Movement, P&G and its brands are proud to be advancing access to sport and everyday inclusion in the host country of the Olympic and Paralympic Games.

Promoting Access to Para Sport: P&G Italy is contributing through concrete initiatives aimed at promoting and facilitating access to sport for young people with disabilities, encouraging a healthy lifestyle, and fostering inclusion and socialization. Among these initiatives are the creation of tools to guide people with disabilities towards sports organizations, support for school events that promote the Paralympic spirit and civic education, the donation of equipment, free sports courses, and many others. Investing in Education and Youth Inclusion: Thanks to the collaboration between P&G and the Fondazione Milano Cortina, as part of the education program Gen26, I'mPOSSIBLE is now reaching Italian schools. The global educational toolkit developed by the International Paralympic Committee (IPC) provides teachers with informative and practical tools to raise awareness of the Paralympic movement and make physical education more accessible and inclusive. About P&G’s Olympic & Paralympic Games Program

P&G has been a Worldwide Partner of the International Olympic Committee (IOC) since 2010 and, since 2020, holds global rights with the International Paralympic Committee (IPC) through the LA28 Games. P&G and its brands have partnered with more than 500 athletes across 37 sports and 17 countries, celebrating their commitment to be the best they can be, just as P&G brands commit to delivering superior performance for people who count on them every day.

About Procter & Gamble

P&G serves consumers around the world with one of the strongest portfolios of trusted, quality leadership brands, including Always, Ambi Pur, Ariel, Bounty, Charmin, Crest, Dawn, Downy, Fairy, Febreze, Gain, Gillette, Head & Shoulders, Lenor, Olay, Oral-B, Pampers, Pantene, SK-II, Tide, Vicks, and Whisper. The P&G community includes operations in approximately 70 countries worldwide. Visit https://www.pg.com for the latest news and information about P&G and its brands. For other P&G news, visit https://www.pg.com/news.

, /PRNewswire/ -- Spire Inc. (NYSE: SR) (the "Company") previously announced that it has delivered notice to holders of the Company's 5.90% Series A Cumulative Redeemable Perpetual Preferred Stock (NYSE: SR.PRA – CUSIP No.: 84857L309) (the "Series A Preferred Stock") of the Company's intent to redeem all 10,000 of its outstanding Series A Preferred Stock, par value $25.00 per share, liquidation preference $25,000 per share, and the corresponding depositary shares of the Company ("Depositary Shares"), each representing 1/1000th fractional interest in one share of Series A Preferred Stock.

As previously disclosed, the redemption date is February 13, 2026 (the "Redemption Date"). The redemption price is equal to $25.00 per Depositary Share (the "Base Redemption Amount"), plus all accrued and unpaid dividends up to, but not including, the Redemption Date (the "Accrued Dividends", and together with the Base Redemption Amount, the "Redemption Price").

The Company previously declared a regular quarterly dividend on the Series A Preferred Stock in an amount equal to $0.36875 per Depositary Share (the "Declared Dividend"), payable on February 17, 2026, for holders of the Series A Preferred Stock as of the previously announced record date, January 26, 2026 (the "Record Date"). Only holders of shares of Series A Preferred Stock as of the Record Date will be entitled to receive the Declared Dividend on February 17, 2026 with respect to such shares.

Payment of the Redemption Price will be made in two parts. First, the Depositary Shares will be redeemed on the Redemption Date at a redemption price equal to the Base Redemption Amount (equivalent to $25,000 per share of the Series A Preferred Stock), payable only to the holders of the Series A Preferred Stock as of the Redemption Date. Second, on February 17, 2026, holders of record of the Series A Preferred Stock as of the Record Date will receive the Declared Dividend, which represents the entirety of the Accrued Dividends.

There are no additional Accrued Dividends payable with respect to the Series A Preferred Stock. Following payment of the Redemption Price, the Company will have no further obligations with respect to dividends or other amounts on the redeemed shares.

Questions relating to, and requests for additional copies of, the notice of redemption and the related materials should be directed to Computershare Trust Company, N.A. for the redemption of the Series A Preferred Stock. The address for the redemption agent is as follows:

Computershare Trust Company, N.A.
Attn: Corporate Actions
150 Royall St., Suite 101
Canton, MA 02021

Investors in the Depositary Shares should contact the bank or broker through which they hold a beneficial interest in the Depositary Shares for information about obtaining the redemption price for the Depositary Shares in which they have a beneficial interest.

About Spire

At Spire Inc. (NYSE: SR) we believe energy exists to help make people's lives better. It's a simple idea, but one that's at the heart of our company. Every day we serve 1.7 million homes and businesses making us one of the largest publicly traded natural gas companies in the country. We help families and business owners fuel their daily lives through our gas utilities serving Alabama, Mississippi and Missouri. Our natural gas-related businesses include Spire Marketing and Spire Midstream. We are committed to transforming our business through growing organically, investing in infrastructure, and driving continuous improvement. Learn more at SpireEnergy.com.

FORWARD-LOOKING AND CAUTIONARY STATEMENTS

This news release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Spire's future operating results may be affected by various uncertainties and risk factors, many of which are beyond the Company's control, including weather conditions, economic factors, the competitive environment, governmental and regulatory policy and action, and risks associated with acquisitions. For a more complete description of these uncertainties and risk factors, see the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2025 and the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2025, each as filed with the Securities and Exchange Commission.

Investor Contact:
Megan McPhail
314-309-6563
[email protected]

Media Contact:
Jason Merrill
314-342-3300
[email protected]

SOURCE Spire Inc.

Key Takeaways EG's premium is expected to rise 4.7%, led by solid performance across Insurance and Reinsurance. The insurance segment is likely to gain from specialty U.S. lines, and property business. Underwriting profit is likely to improve, with a combined ratio of 84.2 and added support from buybacks. Everest Group, Ltd. (EG - Free Report) is expected to register an improvement in its bottom line but a decline in its top line when it reports fourth-quarter 2025 results on Feb. 4, after the closing bell.

The Zacks Consensus Estimate for EG’s fourth-quarter revenues is pegged at $4.31 billion, indicating a 7% decline from the year-ago reported figure.

The consensus estimate for earnings is pegged at $13.36 per share. The Zacks Consensus Estimate for EG’s fourth-quarter earnings has increased 0.2% over the past 30 days. The estimate suggests a year-over-year increase of 172.6%.

What the Zacks Model Unveils for EGOur proven model predicts an earnings beat for Everest Group this time around. This is because the stock has the right combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), which increases the chances of an earnings beat.

Earnings ESP: Everest Group has an Earnings ESP of +1.72%. This is because the Most Accurate Estimate of $13.59 is pegged higher than the Zacks Consensus Estimate of $13.36. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Zacks Rank: EG carries a Zacks Rank #3 at present.

Factors Likely to Shape EG’s Q4 ResultsPremium growth is likely to have been driven by the solid performance of EG’s Reinsurance and Insurance segments. We expect the net written premium to increase 4.7% to $4.2 billion in the second quarter.

The Insurance segment is likely to have benefited from an increase in accident and health business, increases in professional liability business and other specialty business within the U.S. portfolio, and increases in property/short tail business in Latin America and Singapore. We estimate premiums earned to increase 6% to $953.6 million in the to-be-reported quarter.

The Reinsurance segment is expected to have benefited from property pro rata business and property catastrophe excess of loss business. A decrease in financial lines business driven by actions taken on the North America casualty business is likely to have offset the upside. We expect premiums earned to improve 2.2% to $3 billion in the third quarter.

Net investment income is likely to have increased from higher limited partnership income and an increase in income from fixed maturity investments. We expect net investment income to be $330.6 million. The Zacks Consensus Estimate is pegged at $456 million.

The top line in the to-be-reported quarter is expected to have gained from higher net written premiums and net investment income.

Rate increases, exposure growth and traditional risk management capabilities are expected to have improved underwriting profitability, leading to an increase in the combined ratio. We expect the combined ratio to be 84.2 in the to-be-reported quarter. The Zacks Consensus Estimate for the metric is pegged at 93.

 We estimate underwriting income from the Insurance segment to be $128.5 million. The same from the Reinsurance segment is expected to be $476.6 million in the to-be-reported quarter.

Total claims & expenses are likely to have increased largely owing to higher incurred losses and loss adjustment expenses, commission, brokerage, taxes and fees and other underwriting expenses. We expect the metric to be $3.4 billion.

Share buybacks in the to-be-reported quarter are anticipated to have provided a boost to the bottom line.

Other Stocks to ConsiderHere are some other insurance stocks you may want to consider, as our model shows that these, too, have the right combination of elements to post an earnings beat:

The Allstate Corporation (ALL - Free Report) has an Earnings ESP of +3.47% and a Zacks Rank #3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for fourth-quarter 2025 earnings is pegged at $9.82 per share, indicating a year-over-year increase of 28%.

ALL’s earnings beat estimates in each of the last four quarters.

RenaissanceRe Holdings Ltd. (RNR - Free Report) has an Earnings ESP of +6.64% and carries a Zacks Rank of 3 at present. The Zacks Consensus Estimate for fourth-quarter 2025 earnings is $10.59 per share, representing an 31.3% increase from the year-ago reported figure.

RNR’s earnings beat estimates in three of the last four quarters while missing in one.

The Hanover Insurance Group, Inc. (THG - Free Report) has an Earnings ESP of +11.15% and carries a Zacks Rank of 2 at present. The Zacks Consensus Estimate for fourth-quarter 2025 earnings is $5.08 per share, representing an 4.5% decrease from the year-ago reported figure.

THG’s earnings beat estimates in each of the last four quarters.

Key Takeaways Pre-Markets Start a New Trading Week "Risk Off"Jobs Week Starts Tomorrow with JOLTS, Ending with BLS NumbersQ4 Earnings Season Starts Its Busiest Week So Far Monday, February 2nd, 2026

Pre-market futures are trading in the red at this hour, but well up from the early-morning troughs between -1% and the Nasdaq and Russell 2000 -1.75%. Currently, the Dow is down a mere -0.12%, the S&P 500 -0.45%, the Nasdaq -0.71% and the small-cap Russell 2000 -0.38%. We’re still technically “risk off” until further notice, but clearly we’ve made improvements.

We’re quiet to start a new trading week in terms of economic prints, although after the open we’ll get January Manufacturing data from both the S&P Manufacturing Index and ISM Manufacturing. These have been on either side of the 50-level, which depicts whether there is growth or loss. Last time around, the ISM was a mere +47.9% and the S&P +51.9%.

This is also Jobs Week, which begins tomorrow with the Job Openings and Labor Turnover Survey (JOLTS), continues Wednesday with private-sector payrolls from Automatic Data Processing (ADP - Free Report) , Thursday morning’s normal Weekly Jobless Claims and Friday’s Big Kahuna, The Employment Situation report from the U.S. Bureau of Labor Statistics (BLS). The Fed is currently under the impression that the labor market is stabilizing; this week will either confirm or contradict this.

Biggest Q4 Earnings Week So Far
Even though last week we saw lots of marquee names report earnings, the total count dwarfs what we’ve seen in previous weeks thus far for Q4. As many as 700 companies will put out earnings this week alone.

The Walt Disney Company (DIS - Free Report) officially posted a mixed fiscal Q1 report this morning, with earnings of $1.63 per share outpacing the $1.57 in the Zacks consensus (though still below the $1.76 per share reported a year ago), but revenues coming in a hair light of expectations to $25.98 billion. This, even with its Experiences sector (including Parks & Cruises) notching a record-high $10 billion in revenues for the quarter.

Over the weekend, Disney revealed that its long-term CEO, Bob Iger, would be re-retiring from his post by the end of the year. Iger took back the head job at the corporation back in November of 2022, after two years as the sole Executive Chairman. No successor has yet been named; this may be leading the -2.5% selloff in today’s pre-market. For more on DIS' earnings, click here.

Tyson Foods (TSN - Free Report) also put up mixed results in its fiscal Q1 report this morning, reversing Disney’s output with a miss on the bottom line — earnings of 97 cents per share, -4 cents from the Zacks consensus — and a beat of +1.36% to $14.31 billion on the top. The meat-producing giant had been up more than +1% on the news, but the “risk off” morning of trading has dragged shares down -0.5%. For more on TSN’s earnings, click here.

Earnings Reports Expected This Week
It may seem like we’re going to have six more weeks of Q4 earnings season (with apologies to Punxsutawney Phil), but it won’t be quite that long. Putting a bow on 2025 performance — with an outlook toward future quarter gains — is what Q4 earnings are all about.

After the close today, we’ll see Q4 results from Palantir PLTR and NXP Semiconductors (NXPI - Free Report) , which are both expected to post year-over-year growth, but by varying manner of degree: Palantir looks to grow both earnings and sales by more than +60% from this time a year ago, while NXPI looks for +3.77% earnings growth and +6.18% on revenues.

Mag 7 members (for however much longer we hang onto this grouping; it may be time for a recalibration soon) Alphabet GOOGL and Amazon (AMZN - Free Report) will be reporting quarterly earnings on Wednesday and Thursday afternoon, respectively. We’ll also see a bevy of Big Pharma reports: Pfizer (PFE - Free Report) , Merck (MRK - Free Report) , AbbVie (ABBV - Free Report) , Lilly (LLY - Free Report) and Bristol Myers (BMY - Free Report) , as well as Big Tech: AMD (AMD - Free Report) and Qualcomm (QCOM - Free Report) .

Questions or comments about this article and/or author? Click here>>

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Ulta Beauty (ULTA - Free Report) .

Ulta currently has an average brokerage recommendation (ABR) of 1.79, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 26 brokerage firms. An ABR of 1.79 approximates between Strong Buy and Buy.

Of the 26 recommendations that derive the current ABR, 16 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 61.5% and 3.9% of all recommendations.

Brokerage Recommendation Trends for ULTA

Check price target & stock forecast for Ulta here>>>

While the ABR calls for buying Ulta, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.

Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.

This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.

With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near-term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision.

Zacks Rank Should Not Be Confused With ABRIn spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.

The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.

Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.

On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.

There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.

Is ULTA a Good Investment?In terms of earnings estimate revisions for Ulta, the Zacks Consensus Estimate for the current year has increased 0.2% over the past month to $25.57.

Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term.

The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #1 (Strong Buy) for Ulta. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Therefore, the Buy-equivalent ABR for Ulta may serve as a useful guide for investors.

Hexcel (HXL - Free Report) reported $491.3 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 3.7%. EPS of $0.52 for the same period compares to $0.52 a year ago.

The reported revenue represents a surprise of +2.7% over the Zacks Consensus Estimate of $478.38 million. With the consensus EPS estimate being $0.50, the EPS surprise was +4.31%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Hexcel performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Net Sales- Commercial Aerospace- Composite Materials: $257.9 million versus the three-analyst average estimate of $246.71 million. The reported number represents a year-over-year change of +10.3%.Net Sales- Defense, Space & Other- Composite Materials: $136.6 million versus the three-analyst average estimate of $129.02 million. The reported number represents a year-over-year change of +24%.Net Sales- Commercial Aerospace- Engineered Products: $41.6 million versus $46.92 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -6.5% change.Net Sales- Engineered products: $98.5 million compared to the $101.09 million average estimate based on three analysts. The reported number represents a change of -0.2% year over year.Net Sales- Defense, Space & Other- Engineered Products: $55.2 million versus $54.17 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +4% change.Net Sales- Composite Materials: $415.1 million versus the three-analyst average estimate of $375.72 million. The reported number represents a year-over-year change of +5%.Net Sales- Defense, Space & Other- Total: $191.8 million compared to the $183.59 million average estimate based on two analysts. The reported number represents a change of +17.5% year over year.Net Sales- Commercial Aerospace- Total: $299.5 million versus $292.24 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +7.6% change.Operating income- Composite Materials: $85.2 million versus $39.49 million estimated by three analysts on average.Operating income- Corporate & Other: $-31.8 million versus the three-analyst average estimate of $-3.22 million.Operating income- Engineered Products: $8 million versus $16.67 million estimated by three analysts on average.View all Key Company Metrics for Hexcel here>>>

Shares of Hexcel have returned +7.7% over the past month versus the Zacks S&P 500 composite's +0.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Here at Zacks, we offer our members many different opportunities to take full advantage of the stock market, as well as how to invest in ways that lead to long-term success.

One of our most popular services, Zacks Premium offers daily updates of the Zacks Rank and Zacks Industry Rank; full access to the Zacks #1 Rank List; Equity Research reports; and Premium stock screens like the Earnings ESP filter. All are useful tools to find what stocks to buy, what to sell, and what are today's hottest industries.

It also includes the Focus List, a long-term portfolio of top stocks that have all the elements to beat the market.

Breaking Down the Zacks Focus ListIf you could, wouldn't you jump at the chance for access to a curated list of stocks to kickstart your investing journey?

Enter the Zacks Focus List. It's a portfolio made up of 50 stocks that are set to beat the market over the next 12 months; each company selected serves as a foundation for long-term investors looking to create an individual portfolio.

Additionally, each selection is accompanied by a full Zacks Analyst Report, something that makes the Focus List even more valuable. The report explains in detail why each stock was picked and why we believe it's good for the long-term.

The portfolio's past performance only solidifies why investors should consider it as a starting point. For 2020, the Focus List gained 13.85% on an annualized basis compared to the S&P 500's return of 9.38%. Cumulatively, the portfolio has returned 2,519.23% while the S&P returned 854.95%. Returns are for the period of February 1, 1996 to March 31, 2021.

Focus List MethodologyWhen stocks are picked for the Focus List, it reflects our enduring reliance on the power of earnings estimate revisions.

Brokerage analysts are in charge of determining a company's growth and profitability expectations, or earnings estimates. These analysts work together with company management to evaluate all factors that may affect future earnings, like interest rates, the economy, and sector and industry optimism.

Investors also need to look at what a company will earn down the road. This is why earnings estimate revisions are so important.

When a stock receives upward earnings estimate revisions, it will likely get even more positive changes in the future. For instance, if an analyst raised their earnings outlook last month, they'll probably do so again this month, and other analysts will follow.

Utilizing the power of earnings estimate revisions is when the Zacks Rank joins the party. A unique, proprietary stock-rating model, the Zacks Rank uses changes to quarterly earnings expectations to help investors create a winning portfolio.

There are four main factors behind the Zacks Rank: Agreement, Magnitude, Upside, and Surprise. Each one of these features is then given a raw score that's recalculated every night and compiled into the Rank. Using this data, stocks are classified into five groups, ranging from "Strong Buy" to "Strong Sell."

The Focus List is comprised of stocks hand-picked from a long list of #1 (Strong Buy) or #2 (Buy) ranked companies, meaning that each new addition boasts a bullish earnings consensus among analysts.

Since stock prices respond to revisions, it can be very profitable to buy stocks with rising earnings estimates. By buying Focus List stocks, then, you're likely getting into companies whose future earnings estimates will be raised, potentially leading to price momentum.

Focus List Spotlight: Goldman Sachs (GS - Free Report) Founded in 1869, The Goldman Sachs Group, Inc. is a leading global financial holding company providing IB, securities, investment management, and consumer banking services to a diversified client base. The company is headquartered in New York, with offices in major financial centers globally.

Since being added to the Focus List on July 11, 2018 at $226.85 per share, shares of GS have increased 312.35% to $935.41. The stock is currently a #2 (Buy) on the Zacks Rank.

For fiscal 2026, six analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $1.77 to $56.62. GS boasts an average earnings surprise of 14%.

Additionally, GS's earnings are expected to grow 10.3% for the current fiscal year.

Reveal Winning StocksUnlock all of our powerful research, tools and analysis, including the Zacks #1 Rank List, Equity Research Reports, Zacks Earnings ESP Filter, Premium Screener and more, as part of Zacks Premium. You'll quickly identify which stocks to buy, hold and sell, and target today's hottest industries, to help improve the performance of your portfolio. Gain full access now >>

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?

Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Home Depot (HD - Free Report) .

Home Depot currently has an average brokerage recommendation (ABR) of 1.90, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 36 brokerage firms. An ABR of 1.90 approximates between Strong Buy and Buy.

Of the 36 recommendations that derive the current ABR, 21 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 58.3% and 2.8% of all recommendations.

Brokerage Recommendation Trends for HD

Check price target & stock forecast for Home Depot here>>>

While the ABR calls for buying Home Depot, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.

Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation.

In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement.

Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.

ABR Should Not Be Confused With Zacks RankAlthough both Zacks Rank and ABR are displayed in a range of 1--5, they are different measures altogether.

The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.

It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.

On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.

There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.

Is HD Worth Investing In?Looking at the earnings estimate revisions for Home Depot, the Zacks Consensus Estimate for the current year has declined 0% over the past month to $14.5.

Analysts' growing pessimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates lower, could be a legitimate reason for the stock to plunge in the near term.

The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #4 (Sell) for Home Depot. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Therefore, it could be wise to take the Buy-equivalent ABR for Home Depot with a grain of salt.

For the quarter ended December 2025, Aptiv PLC (APTV - Free Report) reported revenue of $5.15 billion, up 5% over the same period last year. EPS came in at $1.86, compared to $1.75 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $5.08 billion, representing a surprise of +1.46%. The company delivered an EPS surprise of +2.23%, with the consensus EPS estimate being $1.82.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how APTIV HLDS LTD performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Net Sales- Eliminations and Other: $-212 million compared to the $-144.22 million average estimate based on five analysts. The reported number represents a change of +1313.3% year over year.Net Sales- Advanced Safety and User Experience: $1.42 billion versus the five-analyst average estimate of $1.44 billion. The reported number represents a year-over-year change of +2.8%.Adjusted Operating Income- Advanced Safety and User Experience: $161 million versus the five-analyst average estimate of $174.86 million.View all Key Company Metrics for APTIV HLDS LTD here>>>

Shares of APTIV HLDS LTD have returned -3.4% over the past month versus the Zacks S&P 500 composite's +0.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Commvault Systems (CVLT - Free Report) .

Commvault currently has an average brokerage recommendation (ABR) of 1.43, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 14 brokerage firms. An ABR of 1.43 approximates between Strong Buy and Buy.

Of the 14 recommendations that derive the current ABR, 11 are Strong Buy, representing 78.6% of all recommendations.

Brokerage Recommendation Trends for CVLT

Check price target & stock forecast for Commvault here>>>

While the ABR calls for buying Commvault, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.

Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.

In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement.

With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near-term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision.

ABR Should Not Be Confused With Zacks RankAlthough both Zacks Rank and ABR are displayed in a range of 1--5, they are different measures altogether.

Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.

It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.

On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.

Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.

Is CVLT Worth Investing In?In terms of earnings estimate revisions for Commvault, the Zacks Consensus Estimate for the current year has increased 24.9% over the past month to $4.19.

Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term.

The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #1 (Strong Buy) for Commvault. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Therefore, the Buy-equivalent ABR for Commvault may serve as a useful guide for investors.

From a technical perspective, Deckers (DECK - Free Report) is looking like an interesting pick, as it just reached a key level of support. DECK recently overtook the 50-day moving average, and this suggests a short-term bullish trend.

The 50-day simple moving average is one of three major moving averages used by traders and analysts to determine support or resistance levels for a wide range of securities. But the 50-day is considered to be more important because it's the first marker of an up or down trend.

DECK has rallied 11.8% over the past four weeks, and the company is a Zacks Rank #3 (Hold) at the moment. This combination suggests DECK could be on the verge of another move higher.

The bullish case only gets stronger once investors take into account DECK's positive earnings estimate revisions. There have been 5 higher compared to none lower for the current fiscal year, and the consensus estimate has moved up as well.

Investors may want to watch DECK for more gains in the near future given the company's key technical level and positive earnings estimate revisions.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Celestica (CLS - Free Report) .

Celestica currently has an average brokerage recommendation (ABR) of 1.41, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 17 brokerage firms. An ABR of 1.41 approximates between Strong Buy and Buy.

Of the 17 recommendations that derive the current ABR, 13 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 76.5% and 5.9% of all recommendations.

Brokerage Recommendation Trends for CLS

Check price target & stock forecast for Celestica here>>>

The ABR suggests buying Celestica, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.

Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation.

In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement.

With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near-term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision.

ABR Should Not Be Confused With Zacks RankIn spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.

Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.

Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.

In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.

Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.

There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.

Is CLS a Good Investment?In terms of earnings estimate revisions for Celestica, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $8.28.

Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.

The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Celestica. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Celestica.